EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Mabpharm's Enterprise Value is HK$1,518.26 Mil.
Mabpharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$41.95 Mil. Therefore, Mabpharm's EV-to-FCF for today is 36.19.
The historical rank and industry rank for Mabpharm's EV-to-FCF or its related term are showing as below:
HKSE:02181'
s EV-to-FCF Range Over the Past 10 Years
Min: -15.64 Med: -8.12 Max: 51.42
Current: 36.19
During the past 7 years, the highest EV-to-FCF of Mabpharm was 51.42. The lowest was -15.64. And the median was -8.12.
HKSE:02181's EV-to-FCF is ranked worse than 75.2% of 379
companies
in the Biotechnology industry
Industry Median: 8.31
vs HKSE:02181: 36.19
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-06-06), Mabpharm's stock price is HK$0.365.
Mabpharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.055. Therefore, Mabpharm's PE Ratio for today is At Loss.
Mabpharm EV-to-FCF Historical Data
The historical data trend for Mabpharm's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Mabpharm's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mabpharm's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Mabpharm's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Mabpharm's EV-to-FCF falls into.
Mabpharm's current Enterprise Value is HK$1,518.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mabpharm's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was HK$41.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mabpharm (HKSE:02181) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Mabpharm's share price for today is HK$0.365.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mabpharm's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.055.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Mabpharm EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Mabpharm's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Mabpharm Ltd is a biopharmaceutical company. The company is engaged in the research, development, and production of new drugs and biosimilars for cancers and autoimmune diseases. Its core products include CMAB008 (infliximab), CMAB007 (omalizumab), and CMAB009 (cetuximab).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02181 has been successfully added to your 